1 / 1

Quel schéma thérapeutique choisir pour le sunitinib dans le cancer du rein métastatique ?

Quel schéma thérapeutique choisir pour le sunitinib dans le cancer du rein métastatique ?. Randomized phase II study of sunitinib 50 mg 4/6w versus 37.5 mg continuous dosing 59 centers in US 292 patients with mRCC enrolled Compared to the phase III study on sunitinib:

zia
Download Presentation

Quel schéma thérapeutique choisir pour le sunitinib dans le cancer du rein métastatique ?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Quel schéma thérapeutique choisir pour le sunitinib dans le cancer du rein métastatique ? • Randomized phase II study of sunitinib 50 mg 4/6w versus 37.5 mg continuous dosing • 59 centers in US • 292 patients with mRCC enrolled • Compared to the phase III study on sunitinib: • more poor risk group (11 vs 6%) • fewer good prognostic group (28 vs 38%) • lower prior nephrectomy (79 vs 91%) • no information on histology • Primary endpoint: Time to disease progression Fig 2. Kaplan-Meier estimate of time to tumor progression by treatment arm. CDD, continuous daily dosing; HR, hazard ratio; Schedule 4/2, sunitinib 50 mg/d for 4 weeks followed by 2 weeks of treatment. Fig 3. Kaplan-Meier estimate of overall survival by treatment arm. CDD, continuous daily dosing; HR, hazard ratio; Schedule 4/2, sunitinib 50 mg/d for 4 weeks followed by 2 weeks of treatment.

More Related